ImmunoBiochem pipeline consists of potentiated biologics for oncology. IMB-212, IMB-213I and IMB-214R carry potent chemotherapeutic, immunomodulatory and radioactive payloads, respectively, and are in development for a number of solid malignancies, including rare, orphan cancers.

IMB-212
IMB-212 is a novel antibody-drug conjugate that is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-212 is based on ImmunoBiochem's proprietary technology platform that enables it to target select secreted proteins amplified in the tumor microenvironment and possessing unique tumor biology. This targeting approach overcomes the challenges of solid tumor heterogeneity and tumor penetration by antibodies. IMB-212 carries a clinically-proven cytotoxic payload and is currently at the preclinical stage of development.

IMB-213I
IMB-213I is a novel antibody carrying a potent immunomodulatory payload aimed at the innate immune system. IMB-213I is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-213I is based on ImmunoBiochem's proprietary technology platform that enables it to target select secreted proteins amplified in the tumor microenvironment and possessing unique tumor biology. IMB-213I designed for the selective and efficacious delivery of its immunomodulatory payload to important immune cells within the tumor and tumor stroma, differentiating it from most other antibodies carrying immunomodulatory payloads in development that are aimed at surface-expressed tumor targets for delivery of such payload into tumor cells.

IMB-214R
IMB-214R is a novel radioimmunoconjugate that is targeted at an undisclosed tumor antigen in the secretome of cancer cells. IMB-214R is based on ImmunoBiochem's proprietary technology platform that enables it to target select secreted proteins amplified in the tumor microenvironment and possessing unique tumor biology. IMB-214R carries a unique radioactive payload and is currently at the preclinical stage of development.